BioMarin Pharmaceutical Sets Its Sights on $2 Billion

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 8, 2018 at 12:02 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,730
    Likes Received:
    3
    via BioMarin Pharmaceutical (NASDAQ:BMRN) continued to increase sales of its drugs in the second quarter, adding its seventh commercial product this quarter as it drives toward GAAP profitability. (It's already there on an adjusted basis.)

    article source
     

  2. anonymous

    anonymous Guest

    What a disaster - there is a child running BD with no deal experience or any worthy experience what so ever - they will never get a deal done. Heard JJ wanted this woman to take over BD after seeing a low-cut blouse. Where is Baker Bros when you want them? Total violation of shareholder fiduciary duty.
     
  3. anonymous

    anonymous Guest

    Brinda Balakrishnan is MD PHD but no deal experience needed for a company like BioMarin. She was some low level search and evaluation person at Genzyme for 9 months and then dabbled in a start up that pushed her out after two years. Iā€™m not sure what JJ saw to make Brinda lead his BD group. In any other company Brinda would be a senior associate or a manager in a BD group.
     
  4. anonymous

    anonymous Guest

    she was an intern at Genentech on the cardio bd group doing landscape stuff. It was an arrangement she had with Genzyme while waiting to get the offer from McKinsey. NO BD EXPERIENCE.